Rockefeller Capital Management L.P. Takes $1.17 Million Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Rockefeller Capital Management L.P. bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,034 shares of the medical equipment provider's stock, valued at approximately $1,167,000.

A number of other institutional investors have also recently bought and sold shares of the business. Van ECK Associates Corp lifted its stake in Zimmer Biomet by 5.9% during the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after purchasing an additional 218,688 shares during the period. Franklin Resources Inc. lifted its holdings in shares of Zimmer Biomet by 398.7% during the fourth quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider's stock valued at $369,469,000 after acquiring an additional 2,796,372 shares during the period. Norges Bank bought a new stake in shares of Zimmer Biomet in the 4th quarter worth about $216,223,000. FMR LLC grew its stake in Zimmer Biomet by 91.6% during the fourth quarter. FMR LLC now owns 1,438,011 shares of the medical equipment provider's stock worth $151,897,000 after buying an additional 687,675 shares during the last quarter. Finally, Equity Investment Corp boosted its holdings in shares of Zimmer Biomet by 57.2% in the 4th quarter. Equity Investment Corp now owns 1,021,062 shares of the medical equipment provider's stock worth $107,855,000 after acquiring an additional 371,653 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company's stock.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the sale, the senior vice president now owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Barclays decreased their target price on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a report on Monday, February 10th. Stifel Nicolaus raised their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a "buy" rating in a research report on Thursday, January 23rd. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Raymond James decreased their price target on Zimmer Biomet from $126.00 to $119.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Finally, Truist Financial reiterated a "hold" rating and set a $113.00 target price (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $124.15.

Zimmer Biomet Stock Performance

Shares of ZBH traded up $2.05 during mid-day trading on Thursday, reaching $101.50. The company's stock had a trading volume of 1,972,259 shares, compared to its average volume of 1,662,354. The stock has a market cap of $20.08 billion, a P/E ratio of 22.81, a PEG ratio of 1.95 and a beta of 0.84. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. The business has a 50-day simple moving average of $105.80 and a two-hundred day simple moving average of $106.57. Zimmer Biomet Holdings, Inc. has a 1-year low of $93.10 and a 1-year high of $123.96.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the firm posted $2.20 EPS. As a group, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.95%. Zimmer Biomet's dividend payout ratio is currently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.